In Vivo Base Editing in Humans: Landmark NEJM Trial of VERVE-102 Durably Lowers Cholesterol
In Vivo Base Editing in Humans: Landmark NEJM Trial of VERVE-102 Durably Lowers Cholesterol In a major milestone for genetic medicine, researchers have demonstrated that a single infusion of a CRIS…